Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Medical uses  



1.1  Malaria  





1.2  Other  







2 Adverse effects  



2.1  Contraindications  







3 Pharmacology  





4 References  














Sulfadoxine/pyrimethamine






العربية
Español
فارسی

ି
Português
Українська
Tiếng Vit
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Sulfadoxine/pyrimethamine
Combination of
SulfadoxineSulfonamide
PyrimethamineAntiparasitic
Clinical data
Pronunciationpeer-i-METH-a-meen/sul-fa-DOX-een[1]
Trade namesFansidar, Fanlar, others
AHFS/Drugs.comConsumer Drug Information
License data
Pregnancy
category
  • AU:C
  • Routes of
    administration
    By mouth
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • Identifiers
    CAS Number
    KEGG
      (verify)

    Sulfadoxine/pyrimethamine, sold under the brand name Fansidar, is a combination medication used to treat malaria.[1][2] It contains sulfadoxine (asulfonamide) and pyrimethamine (anantiprotozoal).[3] For the treatment of malaria it is typically used along with other antimalarial medication such as artesunate.[3] In areas of Africa with moderate to high rates of malaria, three doses are recommended during the second and third trimester of pregnancy.[4]

    Side effects include diarrhea, rash, itchiness, headache, and hair loss.[3][1] Rarely a severe allergic reaction or rash such as toxic epidermal necrolysis, may occur.[1] It is not generally recommended in people with a sulfonamide allergy or significant liverorkidney disease.[3] It works by blocking malaria's ability to use folinic acid.[1]

    Sulfadoxine/pyrimethamine was initially approved for medical use in the United States in 1981.[1] It is on the World Health Organization's List of Essential Medicines.[5] It is not commercially available in the United States.[1]

    Medical uses[edit]

    Malaria[edit]

    It is approved in the United States as a treatment and preventive measure against malaria.[6] The combination is considered to be more effective in treating malaria caused by Plasmodium falciparum than that caused by P. vivax, for which chloroquine is considered more effective, though in the absence of a species-specific diagnosis, the sulfadoxine-pyrimethamine combination may be indicated.[7] Due to side effects, however, it is no longer recommended as a routine preventive,[8] but only to treat serious malaria infections or to prevent them in areas where other drugs may not work.[9] However, it is recommended by the World Health Organization (WHO) for seasonal preventative use in children when combined with amodiaquine.[10]

    Other[edit]

    It has also be used as a treatment and prophylactic measure for toxoplasmosis and Pneumocystis jiroveci pneumonia.[11][12][13][14][15][16]

    Adverse effects[edit]

    Adverse effects by incidence include:[6][11][17][18]

    Common (>1% frequency):

    Rare (<1% frequency):

  • Toxic epidermal necrolysis
  • Agranulocytosis
  • Aplastic anaemia
  • Disorder of haematopoietic structure
  • Drug-induced eosinophilia
  • Thrombocytopaenia
  • Liver necrosis
  • Hepatitis
  • Jaundice
  • Hepatomegaly
  • Nephrotoxicity
  • Unknown frequency:

    • Weight loss
  • Abdominal cramps
  • Hair loss
  • Photosensitivity
  • Fatigue
  • Fever
  • Polyneuritis
  • Atrophic glossitis
  • Gastritis
  • Contraindications[edit]

    Use of this drug is contraindicated in:[6][17]

    Pharmacology[edit]

    Sulfadoxine is a sulfonamide antibiotic that competes with p-aminobenzoic acid in the biosynthesis of folate.[6] Pyrimethamine serves as a selective inhibitor of protozoal dihydrofolate reductase, hence preventing the synthesis of tetrahydrofolate — the active form of folate.[6] A great degree of synergy occurs between the two drugs due to their inhibition of two different steps in the biosynthesis of tetrahydrofolate.[6]

    Pharmacokinetics
    Pharmacokinetic parameter Pyrimethamine Sulfadoxine
    Half-life 111 hours 169 hours
    Cmax 0.2 mg/L 60 mg/L
    Tmax 4 hours 4 hours
    Protein bound 87% 90%
    Excretion Renal (16-30%) Renal (30%)
    Metabolism Hepatic Hepatic

    References[edit]

    1. ^ a b c d e f g "Pyrimethamine/sulfadoxine: Indications, Side Effects, Warnings - Drugs.com". www.drugs.com. Archived from the original on 20 December 2016. Retrieved 11 December 2016.
  • ^ World Health Organization (2015). The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/189763. ISBN 9789241209946. ISSN 0512-3054. WHO technical report series;994.
  • ^ a b c d World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 187–91, 198–200. hdl:10665/44053. ISBN 9789241547659.
  • ^ "Intermittent preventive treatment in pregnancy (IPTp)". WHO. Archived from the original on 5 March 2014. Retrieved 22 May 2020.
  • ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  • ^ a b c d e f "Pyrimethamine, Sulfadoxine and Pyrimethamine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 9 January 2014. Retrieved 9 January 2014.
  • ^ JAMA -Abstract: Sulfadoxine-Pyrimethamine, Chlorproguanil-Dapsone, or Chloroquine for the Treatment of Plasmodium vivax Malaria in Afghanistan and Pakistan: A Randomized Controlled Trial, May 23/30, 2007, Leslie et al. 297 (20): 2201 Archived 9 July 2008 at the Wayback Machine.
  • ^ "Medical Treatment - Sulphadoxine and Pyrimethamine". Archived from the original on 28 December 2007. Retrieved 31 August 2011.
  • ^ Pyrimethamine and Sulfadoxine (Oral Route) - MayoClinic.com Archived 12 June 2011 at the Wayback Machine.
  • ^ World Health Organization (August 2013). Seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus amodiaquine in children: a field guide. Geneva: World Health Organization (WHO). hdl:10665/85726. ISBN 978-92-4-150473-7.
  • ^ a b "Fansidar, Pyrimethamine-sulfadoxine (pyrimethamine/sulfadoxine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 9 January 2014. Retrieved 9 January 2014.
  • ^ Bath PM, Lillicrap DA, Winter M (June 1987). "Fansidar--a treatment for AIDS-related pneumocystis?". Postgraduate Medical Journal. 63 (740): 509–510. doi:10.1136/pgmj.63.740.509-a. PMC 2428336. PMID 3501583.
  • ^ Foot AB, Garin YJ, Ribaud P, Devergie A, Derouin F, Gluckman E (August 1994). "Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients". Bone Marrow Transplantation. 14 (2): 241–245. PMID 7994239.
  • ^ Bessesen MT, Miller LA, Cohn DL, Bartlett S, Ellison RT (March 1995). "Administration of pyrimethamine/sulfadoxine for prevention of Pneumocystis carinii pneumonia in patients with AIDS". Clinical Infectious Diseases. 20 (3): 730–731. doi:10.1093/clinids/20.3.730. PMID 7756514.
  • ^ Michalová K, Ríhová E, Havlíková M (July 1996). "[Fansidar in the treatment of toxoplasmosis]". Ceska a Slovenska Oftalmologie (in Czech). 52 (3): 173–178. PMID 8768475.
  • ^ Schürmann D, Bergmann F, Albrecht H, Padberg J, Grünewald T, Behnsch M, et al. (January 2001). "Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS". The Journal of Infection. 42 (1): 8–15. doi:10.1053/jinf.2000.0772. PMID 11243747.
  • ^ a b Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. p. 429. ISBN 978-0-85711-084-8.
  • ^ "Fansidar (sulfadoxine and pyrimethamine)" (PDF). medicines.org.au. Roche Products Pty Limited. 17 April 2008. Archived (PDF) from the original on 9 January 2014. Retrieved 9 January 2014.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Sulfadoxine/pyrimethamine&oldid=1215244480"

    Categories: 
    Antimalarial agents
    Drugs developed by Hoffmann-La Roche
    World Health Organization essential medicines
    Hidden categories: 
    Webarchive template wayback links
    CS1 Czech-language sources (cs)
    Articles with short description
    Short description matches Wikidata
    Use dmy dates from March 2024
    Articles without EBI source
    Chemical pages without ChemSpiderID
    Chemical pages without DrugBank identifier
    Articles without InChI source
    Articles without UNII source
    Drugs that are a combination of chemicals
    Wikipedia medicine articles ready to translate
     



    This page was last edited on 23 March 2024, at 23:41 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki